Share This Link

Amphotericin B: Amphotericin B is a systemic antifungal reserved for severe or life-threatening fungal infections such as systemic candidiasis or cryptococcal meningitis. It carries significant risks including nephrotoxicity, electrolyte disturbances, and infusion reactions. The infant’s has localized oral candidiasis following antibiotic use, which doesn’t t require aggressive systemic therapy.

Ketoconazole (Nizoral): Ketoconazole is an azole antifungal that acts by inhibiting fungal ergosterol synthesis in the cell membrane. Although it can treat certain fungal infections, its systemic use is limited due to the risk of hepatotoxicity and multiple drug interactions. In pediatric patients with uncomplicated oral thrush, systemic azoles are generally avoided.

Itraconazole (Sporanox): Itraconazole is a systemic triazole antifungal that interferes with ergosterol synthesis and is used for more invasive fungal infections such as histoplasmosis, blastomycosis, or refractory mucocutaneous candidiasis. It is not typically used as an initial treatment for simple oral thrush in infants.

She should apply the scabies treatment cream for an hour and wash it off: Standard scabies treatments such as permethrin 5% cream are typically applied to the entire body from the neck down and left on the skin for about 8 to 14 hours before washing off. Leaving the medication on the skin allows adequate penetration into the burrows where Sarcoptes scabiei mites reside.

Scabies may need to be retreated in a week after initial treatment: Retreatment is sometimes recommended, particularly if symptoms persist or if reinfestation occurs. However, when medications such as permethrin are used correctly, a single application can often eradicate the mites. Retreatment after 7 days is considered a secondary step rather than the primary point.

Malathion is flammable and she should take care until the solution dries: Malathion is an organophosphate insecticide sometimes used for lice treatment rather than routine scabies therapy. Although it is flammable and requires caution when drying, it is not the first-line treatment for scabies. Standard scabies education focuses on medications such as permethrin or ivermectin.

Antibiotics: Antibiotics are not part of the routine pharmacologic management of contact dermatitis because the condition is an inflammatory skin reaction triggered by exposure to irritants or allergens rather than a primary bacterial infection. They may only be considered if secondary bacterial infection develops due to scratching and skin barrier disruption.

Topical steroids: Topical corticosteroids are a cornerstone of treatment for contact dermatitis because they reduce cutaneous inflammation by suppressing local immune responses and inflammatory mediator release. These medications decrease erythema, swelling, and pruritus associated with the allergic or irritant reaction.

Antihistamines: Antihistamines are used to relieve pruritus associated with contact dermatitis. Histamine release contributes to the itching sensation, and antihistamines help reduce this symptom and improve comfort. Sedating antihistamines may also assist with sleep in patients experiencing severe nighttime itching, reducing scratching and preventing further skin irritation.

Tacrolimus is the most effective if it is used continuously for 4 to 6 months: Tacrolimus is recommended for short-term or intermittent use in the management of atopic dermatitis, particularly when topical corticosteroids are ineffective or unsuitable for sensitive areas such as the face or skin folds. Continuous long-term use for several months is not advised.

Tacrolimus should be spread generously over the affected area: Tacrolimus ointment should be applied as a thin layer to the affected skin areas rather than being spread generously. Using excessive amounts does not increase therapeutic benefit and may increase local adverse effects such as burning, stinging, or irritation. Appropriate dosing helps reduce systemic exposure.

The FDA recommends patients be screened for cancer before prescribing tacrolimus: Routine cancer screening prior to initiating topical tacrolimus therapy is not recommended by the FDA. The Black Box warning emphasizes cautious use, limiting prolonged exposure, and avoiding unnecessary immunosuppression rather than requiring formal malignancy screening.

Fever up to 104°F after previous DTaP vaccine: A high fever following a previous dose of DTaP may be considered a precaution rather than a true contraindication. Post-vaccination fever can occur due to the immune system’s inflammatory response to vaccine antigens. This reaction alone does not permanently prohibit future vaccination if the benefits outweigh the risks.

Family history of seizures after DTaP vaccine: A family history of seizures is not considered a true contraindication to receiving DTaP or Tdap. Although febrile seizures can occur in young children with fever from any cause, including vaccination, genetic or familial seizure history does not significantly increase the risk of serious neurologic complications from the vaccine.

Adolescent pregnancy: Pregnancy, particularly during adolescence, is not a contraindication to receiving the Tdap vaccine. In fact, Tdap is recommended during each pregnancy, ideally between 27 and 36 weeks of gestation, to stimulate maternal antibody production and provide passive immunity to the newborn against pertussis.

Were born at less than 32 weeks gestation: Prematurity is not an absolute contraindication to the hepatitis B vaccine. Preterm infants are actually recommended to receive the vaccine because they remain vulnerable to hepatitis B virus infection. Although infants with very low birth weight may have a reduced immune response initially, vaccination is still administered with possible adjustments to the schedule based on birth weight and maternal hepatitis B status.

Are pregnant: Pregnancy is not a contraindication to hepatitis B vaccination. The vaccine contains recombinant hepatitis B surface antigen produced through genetic engineering rather than live virus, making it safe in pregnancy. Vaccination during pregnancy may be indicated if the mother is at risk of exposure, helping prevent maternal infection and vertical transmission.

Are on hemodialysis: Individuals undergoing hemodialysis are actually considered a high-risk group for hepatitis B infection due to repeated vascular access and potential exposure to blood products in dialysis settings. For this reason, hepatitis B vaccination is strongly recommended in these patients, often using higher vaccine doses or additional doses.

Increased risk for osteoporosis: Combined oral contraceptives contain estrogen and progestin, and estrogen has a protective effect on bone mineral density. Estrogen supports osteoblastic activity and helps maintain bone remodeling balance, contributing to preservation of bone mass. COCs are not associated with increased osteoporosis risk and may provide some protection.

Increased risk of ovarian and uterine cancers: Use of combined oral contraceptives is associated with a reduced risk of ovarian and endometrial cancers. Suppression of ovulation decreases repeated ovarian epithelial trauma, which lowers the risk of malignant transformation. Progestin components also counteract estrogen-mediated endometrial proliferation, lowering the risk of endometrial hyperplasia.

Increased bleeding and iron deficiency anemia: Combined oral contraceptives generally reduce menstrual blood loss by stabilizing the endometrial lining and suppressing excessive endometrial proliferation. Shorter and lighter menstrual periods occur in many users, which contributes to improved iron stores and may reduce the likelihood of iron deficiency anemia.

Estrogen/progesterone combination: Combination therapy is recommended for postmenopausal women with an intact uterus to reduce menopausal symptoms while preventing endometrial hyperplasia. Progesterone counteracts the proliferative effects of estrogen on the endometrium, lowering the risk of endometrial cancer associated with unopposed estrogen.

IM medroxyprogesterone (Depo Provera): Medroxyprogesterone can be used in postmenopausal women for endometrial protection in combination with estrogen therapy. It helps prevent endometrial hyperplasia and provides additional contraceptive or hormonal support if indicated, making it appropriate for use when combined with estrogen.

Androgens: Androgens may be prescribed in select postmenopausal women for management of hypoactive sexual desire disorder or for severe fatigue and muscle mass loss. They do not stimulate the endometrium and can be used cautiously when indicated, either alone or in combination with estrogen/progesterone therapy.

Regulation of the menstrual cycle: Estrogen plays a central role in the menstrual cycle by stimulating the growth of the endometrium during the follicular phase and regulating the release of gonadotropins through feedback mechanisms on the hypothalamus and pituitary. It ensures proper timing of ovulation and coordination with progesterone for the luteal phase.

Maintenance of bone density by decreasing bone resorption: Estrogen inhibits osteoclast activity, reducing bone resorption and helping preserve bone mineral density. It promotes the balance between bone formation and breakdown, which is essential for preventing osteoporosis, particularly during and after menopause when estrogen levels decline.

Maintenance of the normal structure of the skin and blood vessels: Estrogen supports skin thickness and elasticity by promoting collagen synthesis and maintaining subcutaneous fat. It also contributes to vascular health by improving endothelial function, enhancing vasodilation, and reducing atherosclerotic risk.

A and C: While A and C are correct, this option does not include estrogen’s critical role in bone health, which is a key physiological effect.

The interaction between triptans and estrogen, limiting migraine therapy choices: There is no significant pharmacologic interaction between triptans and estrogen that would limit migraine treatment. Triptans can still be used to manage acute migraine attacks, but the primary concern with estrogen use in migraine with aura is vascular risk rather than drug interactions.

An increased incidence of migraines with the use of estrogen: While estrogen fluctuations can trigger migraines, the main contraindication for women with migraine with aura is not simply an increase in migraine frequency. Estrogen use may exacerbate symptoms, but the critical concern is the potential for serious vascular events, particularly ischemic stroke.

Patients with migraines may be prescribed estrogen without any concerns: Prescribing estrogen without consideration in patients with migraine with aura is contraindicated due to the heightened risk of thromboembolic events and stroke. Alternative non-estrogenic therapies are preferred to manage both contraception and menopausal symptoms safely.